Janet Tomezsko, MD
Urogynecology and Reconstructive Pelvic Surgery · Skokie, ILNPI 1265494041
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $896 of the $1,128 with a category attached, or 79.4%. 11 manufacturers reported payments, led by Boston Scientific at 24.0% of the total. Reporting peaked in 2019 at $784 and has fallen 95.1% since, to $38 in 2023. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in IL, where the typical reported total is $2,778.
Across 18 payments — averaging $62.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$271
- Coloplast$195
- Caldera Medical, Inc$180
- Contura, Inc.$95
- Ferring Pharmaceuticals Inc.$87
- Astellas Pharma US Inc$80
- plus $220 from 5 others
What the payments were for
- Food & beverage$89679%
- Education$23321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 3 | $271 |
| Coloplast | 2 | $195 |
| Caldera Medical, Inc | 1 | $180 |
| Contura, Inc. | 1 | $95 |
| Ferring Pharmaceuticals Inc. | 1 | $87 |
| Astellas Pharma US Inc | 1 | $80 |
| Laborie Medical Technologies Corp. | 2 | $79 |
| Axonics, Inc. | 2 | $55 |
| AbbVie | 3 | $48 |
| Pacira Pharmaceuticals Incorporated | 1 | $19 |
| Covidien LP | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,128 in reported general payments places this provider in the 20th percentile of 62 urogynecology and reconstructive pelvic surgery providers in Illinois.
See all urogynecology and reconstructive pelvic surgery providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 308 | $275,945 |
| GemtesaVibegron | 66 | $53,720 |
| Estradiol | 310 | $20,894 |
| Methenamine Hippurate | 278 | $17,836 |
| Mirabegron ErMirabegron | 20 | $15,908 |
| PremarinEstrogens, Conjugated | 23 | $10,524 |
| Solifenacin Succinate | 214 | $10,078 |
| Trimethoprim | 142 | $6,393 |
| Tolterodine Tartrate ErTolterodine Tartrate | 63 | $3,708 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 29 | $3,241 |
| Trospium Chloride ErTrospium Chloride | 17 | $3,218 |
| Oxybutynin Chloride ErOxybutynin Chloride | 183 | $2,845 |
| Trospium Chloride | 27 | $1,291 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 82 | $995 |
| Cefpodoxime Proxetil | 19 | $673 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $80 | $275,945308 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 62 urogynecology and reconstructive pelvic surgery providers in Illinois.
Other urogynecology and reconstructive pelvic surgery in Skokie
- Peter SandSkokie$185K
- Roger GoldbergSkokie$54K
- Adam Gafni KaneSkokie$7K
- Nani MossSkokie$5K
- Sonia DuttaSkokie$2K
- Ghazaleh Rostami NiaSkokie$735
- Cynthia BrincatSkokie$37
- Abraham ShashouaChicago$339K
- Akira GillinghamChicago$58K
- Kimberly KentonChicago$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.